Compliance Rate
Compliance Rate
100.0%
Compliant submissions
1
Incompliant submissions
0
Total trials
1
My Organizations' Clinical Trials
Showing 2051 of 2051 entries
View as:
Phase: N/A
Priority: Normal
Start: 07/08/16
End: 11/30/22
Due: 11/30/23
| Title | NCT ID | Organization | User | Status | Start Date | End Date | Reporting Due Date | Last Checked | User Role | Org Created |
|---|---|---|---|---|---|---|---|---|---|---|
| Safety and Efficacy Study of Pembrolizumab (MK-3475) in Chinese Participants With Locally Advanced or Metastatic Melanoma (MK-3475-151/KEYNOTE-151) | NCT02821000 | Merck Sharp & Dohme LLC | user2@example.com | None | 2016-07-08 | 2022-11-30 | 2023-11-30 | - | - | 2025-07-14 |